# Neoantigen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neoantigen

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.neoantigen.cn
- Latest round: Angel (Jun 1, 2016)
- Investors on record: 3

## About

Established in 2016 and based in Hangzhou, China, Neoantigen is a biotechnology company that engaged in the research and development of personalized tumor vaccines. Prof. Shuqing Chen, the founder and chairman of the company, was the technical Advisor to the President of Qianyuan Pharmaceutical. The company partners with Innovent, Virogin Biotech and many high schools such as Zhejiang University.

The company focuses on the research and development of various types of personalized immunotherapy products based on neoantigens. The company also built industry chain of nascent antigen-new drug research and development platforms including artificial intelligence automated identification and optimization system, in vitro verification cell platform, personalized peptide drug preparation and quality control system. The company research team comes from Zhejiang University, Harvard University in the United States, UBC University in Canada and etc.

Following the funding in 2021, the company plans to use the investment for clinical trials of its products.

## Funding rounds

- Angel, Jun 1, 2016 — Lanshan Capital, Bangshi Capital, Jicheng Venture Capital

## Investors

- Lanshan Capital (https://capitalatlas.ai/funds/lanshan-capital) — Angel
- Bangshi Capital (https://capitalatlas.ai/funds/bangshi-capital) — Angel
- Jicheng Venture Capital — Angel